These results taken together confirm the efficacy of the PD1/PD-L1 inhibition in previously treated advanced NSCLC, independently from histology and PD-L1 expression also in the elderly population, with 65 years old as cut-off. The gene discussed is CD274; the disease is non-small cell lung carcinoma.